Welcome to LookChem.com Sign In|Join Free

CAS

  • or
3,20-Dioxopregna-1,4,9(11),16-tetraen-21-yl acetate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

37413-91-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 37413-91-5 Structure
  • Basic information

    1. Product Name: 3,20-Dioxopregna-1,4,9(11),16-tetraen-21-yl acetate
    2. Synonyms: Pregna-1,4,9(11),16-tetraen-21-ol-3,20-dione 21-acetate;21-Acetoxypregna-1,4,9(11),16-tetrene-3,20-dione;3,20-Dioxopregna-1,4,9(11),16-tetrene-21-ol acetate;21-(Acetyloxy)-pregna-1,4,9(11),16-tetraene-3,20-dione;2-((8S,10S,13S,14S)-10,13-DiMethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate;21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione;Pregna-1,4,9(11),16-tetraene-3,20-dione,21-(acetyloxy)-;Acetate tetraene Matter
    3. CAS NO:37413-91-5
    4. Molecular Formula: C23H26O4
    5. Molecular Weight: 366.45
    6. EINECS: 253-497-3
    7. Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
    8. Mol File: 37413-91-5.mol
  • Chemical Properties

    1. Melting Point: 173-175°C
    2. Boiling Point: 534.568 °C at 760 mmHg
    3. Flash Point: 233.008 °C
    4. Appearance: /
    5. Density: 1.211 g/cm3
    6. Vapor Pressure: 0mmHg at 25°C
    7. Refractive Index: 1.585
    8. Storage Temp.: Refrigerator
    9. Solubility: N/A
    10. CAS DataBase Reference: 3,20-Dioxopregna-1,4,9(11),16-tetraen-21-yl acetate(CAS DataBase Reference)
    11. NIST Chemistry Reference: 3,20-Dioxopregna-1,4,9(11),16-tetraen-21-yl acetate(37413-91-5)
    12. EPA Substance Registry System: 3,20-Dioxopregna-1,4,9(11),16-tetraen-21-yl acetate(37413-91-5)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 37413-91-5(Hazardous Substances Data)

37413-91-5 Usage

Chemical Properties

White Solid

Check Digit Verification of cas no

The CAS Registry Mumber 37413-91-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,4,1 and 3 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 37413-91:
(7*3)+(6*7)+(5*4)+(4*1)+(3*3)+(2*9)+(1*1)=115
115 % 10 = 5
So 37413-91-5 is a valid CAS Registry Number.
InChI:InChI=1/C23H26O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h7-10,12,17-18H,4-6,11,13H2,1-3H3/t17-,18-,22-,23-/m0/s1

37413-91-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name [2-[(8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

1.2 Other means of identification

Product number -
Other names 2-((8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:37413-91-5 SDS

37413-91-5Synthetic route

pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate
4380-55-6

pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Stage #1: pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate With pyridine; N-chloro-succinimide at -15℃; for 1h; Inert atmosphere;
Stage #2: With sulfur dioxide at -10℃; for 0.5h; Inert atmosphere;
98.8%
prednisolone 21-acetate
52-21-1

prednisolone 21-acetate

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Stage #1: prednisolone 21-acetate With pyridine; N-chloro-succinimide at -15 - 20℃; for 0.416667h; Inert atmosphere;
Stage #2: With sulfur dioxide for 1h; Inert atmosphere;
83.5%
prednisolone 21-acetate
52-21-1

prednisolone 21-acetate

A

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

B

pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate
4380-55-6

pregna-1,4,9(11)-triene-17α,21-diol-3,20-dione 21-acetate

C

2-((10S)-10,17-dimethyl-3-oxo-6,7,8,10,12,15,16,17-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

2-((10S)-10,17-dimethyl-3-oxo-6,7,8,10,12,15,16,17-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

D

C46H54O11S

C46H54O11S

Conditions
ConditionsYield
With pyridine; thionyl chloride In N,N-dimethyl-formamide at 20℃; Reagent/catalyst; Temperature;A 50%
B n/a
C n/a
D n/a
21-acetoxy-pregna-4,9(11),16-triene-3,20-dinone
23460-76-6

21-acetoxy-pregna-4,9(11),16-triene-3,20-dinone

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
With selenium(IV) oxide; tert-butyl alcohol
With pyridine; selenium(IV) oxide In tert-butyl alcohol for 24h; Reflux; Inert atmosphere;25.27 g
2,4,6-trimethyl-pyridine
108-75-8

2,4,6-trimethyl-pyridine

21-acetoxy-2α-bromo-pregna-4,9(11),16-triene-3,20-dione

21-acetoxy-2α-bromo-pregna-4,9(11),16-triene-3,20-dione

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

prednisolon
50-24-8

prednisolon

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: thionyl chloride / tetrahydrofuran / 0.67 h / 0 °C / Inert atmosphere
1.2: 1.25 h / 5 - 20 °C
2.1: dmap / dichloromethane / 0.5 h / 20 °C / Inert atmosphere
3.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / tetrahydrofuran / 3 h / 60 °C / Inert atmosphere
View Scheme
C21H24O3

C21H24O3

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dmap / dichloromethane / 0.5 h / 20 °C / Inert atmosphere
2: 1,8-diazabicyclo[5.4.0]undec-7-ene / tetrahydrofuran / 3 h / 60 °C / Inert atmosphere
View Scheme
18-hydroxypregnane-1,4,9(11),17-tetraene-3,19-dione-18-acetate

18-hydroxypregnane-1,4,9(11),17-tetraene-3,19-dione-18-acetate

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In tetrahydrofuran at 60℃; for 3h; Inert atmosphere;1.92 g
With 1,8-diazabicyclo[5.4.0]undec-7-ene at 50℃; for 5h; Inert atmosphere;27.6 g
C23H27BrO4

C23H27BrO4

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
With potassium acetate; acetic acid In N,N-dimethyl-formamide at 105℃; for 5h; Reagent/catalyst; Solvent; Temperature; Inert atmosphere; Large scale;965 g
androsta-1,4,9(11)-triene-3,17-dione
15375-21-0

androsta-1,4,9(11)-triene-3,17-dione

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: potassium hydroxide / tetrahydrofuran; acetone / 2 h / 0 - 40 °C / Inert atmosphere; Large scale
1.2: 15 h / -5 - 5 °C / Large scale
2.1: dmap; triethylamine / dichloromethane / 7 h / Inert atmosphere; Reflux; Large scale
3.1: N-Bromosuccinimide / acetone; tert-butyl alcohol / 2 h / 10 - 20 °C / Large scale
3.2: 1 h / 30 - 35 °C / Inert atmosphere; Large scale
4.1: potassium acetate; acetic acid / N,N-dimethyl-formamide / 5 h / 105 °C / Inert atmosphere; Large scale
View Scheme
17α-ethynyl-17β-hydroxy-1,4,9(11)-trieneandrostan-3-one

17α-ethynyl-17β-hydroxy-1,4,9(11)-trieneandrostan-3-one

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: dmap; triethylamine / dichloromethane / 7 h / Inert atmosphere; Reflux; Large scale
2.1: N-Bromosuccinimide / acetone; tert-butyl alcohol / 2 h / 10 - 20 °C / Large scale
2.2: 1 h / 30 - 35 °C / Inert atmosphere; Large scale
3.1: potassium acetate; acetic acid / N,N-dimethyl-formamide / 5 h / 105 °C / Inert atmosphere; Large scale
View Scheme
androst-4,9(11)-dien-3,17-dione
1035-69-4

androst-4,9(11)-dien-3,17-dione

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: acetone / 0.5 h / 20 °C
2.1: calcium oxide; calcium chloride; iodine / methanol; dichloromethane; water / 1.5 h / 20 °C / Inert atmosphere
3.1: potassium acetate / N,N-dimethyl-formamide / 2 h / 65 °C / Inert atmosphere
3.2: 0.5 h / Inert atmosphere
4.1: toluene-4-sulfonic acid; trifluoroacetic anhydride / dichloromethane / 2.5 h / 20 °C
4.2: 0.25 h
5.1: potassium acetate / dimethyl sulfoxide / 2 h / 80 °C / Inert atmosphere
5.2: 0.5 h / Inert atmosphere
6.1: pyridine; selenium(IV) oxide / tert-butyl alcohol / 24 h / Reflux; Inert atmosphere
View Scheme
9-alpha-hydroxyandrost-4-ene-3,17-dione
560-62-3, 23015-99-8

9-alpha-hydroxyandrost-4-ene-3,17-dione

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: diethyl ether / 0.5 h / 20 °C
2.1: calcium oxide; calcium chloride; iodine / methanol; dichloromethane; water / 1.5 h / 20 °C / Inert atmosphere
3.1: potassium acetate / N,N-dimethyl-formamide / 2 h / 65 °C / Inert atmosphere
3.2: 0.5 h / Inert atmosphere
4.1: toluene-4-sulfonic acid; trifluoroacetic anhydride / dichloromethane / 2.5 h / 20 °C
4.2: 0.25 h
5.1: potassium acetate / dimethyl sulfoxide / 2 h / 80 °C / Inert atmosphere
5.2: 0.5 h / Inert atmosphere
6.1: pyridine; selenium(IV) oxide / tert-butyl alcohol / 24 h / Reflux; Inert atmosphere
View Scheme
17α-Hydroxy-21-iodopregna-4,9(11)-diene-3,20-dione
95816-38-9

17α-Hydroxy-21-iodopregna-4,9(11)-diene-3,20-dione

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: potassium acetate / N,N-dimethyl-formamide / 2 h / 65 °C / Inert atmosphere
1.2: 0.5 h / Inert atmosphere
2.1: toluene-4-sulfonic acid; trifluoroacetic anhydride / dichloromethane / 2.5 h / 20 °C
2.2: 0.25 h
3.1: potassium acetate / dimethyl sulfoxide / 2 h / 80 °C / Inert atmosphere
3.2: 0.5 h / Inert atmosphere
4.1: pyridine; selenium(IV) oxide / tert-butyl alcohol / 24 h / Reflux; Inert atmosphere
View Scheme
pregna-4,9(11)-diene-3,20-dione-17-hydroxy-21-methyl
34184-82-2

pregna-4,9(11)-diene-3,20-dione-17-hydroxy-21-methyl

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: calcium oxide; calcium chloride; iodine / methanol; dichloromethane; water / 1.5 h / 20 °C / Inert atmosphere
2.1: potassium acetate / N,N-dimethyl-formamide / 2 h / 65 °C / Inert atmosphere
2.2: 0.5 h / Inert atmosphere
3.1: toluene-4-sulfonic acid; trifluoroacetic anhydride / dichloromethane / 2.5 h / 20 °C
3.2: 0.25 h
4.1: potassium acetate / dimethyl sulfoxide / 2 h / 80 °C / Inert atmosphere
4.2: 0.5 h / Inert atmosphere
5.1: pyridine; selenium(IV) oxide / tert-butyl alcohol / 24 h / Reflux; Inert atmosphere
View Scheme
anecortave
7753-60-8

anecortave

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: toluene-4-sulfonic acid; trifluoroacetic anhydride / dichloromethane / 2.5 h / 20 °C
1.2: 0.25 h
2.1: potassium acetate / dimethyl sulfoxide / 2 h / 80 °C / Inert atmosphere
2.2: 0.5 h / Inert atmosphere
3.1: pyridine; selenium(IV) oxide / tert-butyl alcohol / 24 h / Reflux; Inert atmosphere
View Scheme
pregna-4,9(11)-diene-17α,21-diol-3,20-dione 17,21-diacetate
7780-63-4

pregna-4,9(11)-diene-17α,21-diol-3,20-dione 17,21-diacetate

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: potassium acetate / dimethyl sulfoxide / 2 h / 80 °C / Inert atmosphere
1.2: 0.5 h / Inert atmosphere
2.1: pyridine; selenium(IV) oxide / tert-butyl alcohol / 24 h / Reflux; Inert atmosphere
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

N,N-dimethyl-formamide
68-12-2, 33513-42-7

N,N-dimethyl-formamide

C24H27BrO6

C24H27BrO6

Conditions
ConditionsYield
Stage #1: 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate; N,N-dimethyl-formamide With perchloric acid In water at 20 - 27℃; Inert atmosphere;
Stage #2: With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione In water; N,N-dimethyl-formamide at 20 - 35℃; Inert atmosphere;
99%
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

16α,17α,21-trihydroxypregna-1,4,9(11)-triene-3,20-dione-21-acetate
77017-20-0

16α,17α,21-trihydroxypregna-1,4,9(11)-triene-3,20-dione-21-acetate

Conditions
ConditionsYield
Stage #1: 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate With formic acid In acetone at -5 - 0℃; for 0.0833333h;
Stage #2: With potassium permanganate In water; acetone at -5 - 0℃; for 0.166667h;
96%
With potassium permanganate
With potassium permanganate; formic acid In water; acetone at -7 - -3℃; for 0.5h; Industrial scale;15 kg
With potassium permanganate; oxalic acid In water; butanone at -5℃; Reagent/catalyst; Solvent; Temperature;50.5 g
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

C23H26O5

C23H26O5

Conditions
ConditionsYield
Stage #1: 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate With perchloric acid; 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione In water; acetone at -10 - -5℃; for 2h;
Stage #2: With potassium carbonate In water; acetone at -5 - 35℃; for 12h;
96%
Stage #1: 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate With perchloric acid; 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione In acetone at -10 - -5℃;
Stage #2: With potassium carbonate In acetone at 33 - 37℃;
83.36%
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

C23H28O6

C23H28O6

Conditions
ConditionsYield
With potassium permanganate; formic acid In water; acetone at -5 - 0℃; for 0.5h; Solvent; Temperature; Inert atmosphere;86%
(phenylthio)nitromethane
60595-16-6

(phenylthio)nitromethane

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-10,13-dimethyl-16-(nitro-phenylsulfanyl-methyl)-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester
144602-46-0

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-10,13-dimethyl-16-(nitro-phenylsulfanyl-methyl)-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester

Conditions
ConditionsYield
With 1,8-diazabicyclo[5.4.0]undec-7-ene In tetrahydrofuran; tert-butyl alcohol Yield given;
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

methyl-d3-magnesium iodide
41251-37-0

methyl-d3-magnesium iodide

C24H27(2)H3O4

C24H27(2)H3O4

Conditions
ConditionsYield
With methylmagnesium chloride; copper(II) propionate In tetrahydrofuran at -9 - -7℃; for 0.666667h;
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

<14C>methyl iodide
22092-83-7

<14C>methyl iodide

C23(14)CH30O4

C23(14)CH30O4

Conditions
ConditionsYield
With methylmagnesium chloride; copper(II) propionate In tetrahydrofuran at -9 - -7℃; for 0.666667h;
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

17α,21-dihydroxy-16β-methyl-1,4,9(11)-pregnatriene-3,20-dione 21-acetate
910-99-6

17α,21-dihydroxy-16β-methyl-1,4,9(11)-pregnatriene-3,20-dione 21-acetate

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: DBU / 2-methyl-propan-2-ol; tetrahydrofuran
2: 70 percent / HOAc
3: m-chloroperbenzoic acid
5: 90 percent / Wilkinson catalyst
View Scheme
Multi-step reaction with 5 steps
1: DBU / 2-methyl-propan-2-ol; tetrahydrofuran
2: 70 percent / HOAc
3: 57 percent / m-chloroperbenzoic acid
5: 90 percent / Wilkinson catalyst
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Acetic acid 2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-16-methylene-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester
19683-24-0

Acetic acid 2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-16-methylene-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: DBU / 2-methyl-propan-2-ol; tetrahydrofuran
2: 70 percent / HOAc
3: m-chloroperbenzoic acid
View Scheme
Multi-step reaction with 4 steps
1: DBU / 2-methyl-propan-2-ol; tetrahydrofuran
2: 70 percent / HOAc
3: 57 percent / m-chloroperbenzoic acid
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(bis-phenylsulfanyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester
144602-47-1

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(bis-phenylsulfanyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: DBU / 2-methyl-propan-2-ol; tetrahydrofuran
2: 70 percent / HOAc
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(benzenesulfinyl-phenylsulfanyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester
144602-48-2

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(benzenesulfinyl-phenylsulfanyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: DBU / 2-methyl-propan-2-ol; tetrahydrofuran
2: 70 percent / HOAc
3: m-chloroperbenzoic acid
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(bis-benzenesulfinyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester
144602-43-7

Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(bis-benzenesulfinyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: DBU / 2-methyl-propan-2-ol; tetrahydrofuran
2: 70 percent / HOAc
3: 57 percent / m-chloroperbenzoic acid
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

16α,21-diacetoxy-17-hydroxy-pregna-1,4,9(11)-triene-3,20-dione
95943-95-6

16α,21-diacetoxy-17-hydroxy-pregna-1,4,9(11)-triene-3,20-dione

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: KMnO4
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

9β,11β-epoxy-21-hydroxypregna-1,4,16-triene-3,20-dione 21-acetate
103466-44-0

9β,11β-epoxy-21-hydroxypregna-1,4,16-triene-3,20-dione 21-acetate

Isopropenyl acetate
108-22-5

Isopropenyl acetate

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

3,21-diacetyloxy-pregna-1,3,5,9(11),16-pentaene-20-one
1058744-83-4

3,21-diacetyloxy-pregna-1,3,5,9(11),16-pentaene-20-one

Conditions
ConditionsYield
toluene-4-sulfonic acid In water at 80℃; for 4h;
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

6α-fluoro-1,4,9,16-tetraenepregna-3,20-dione-21-acetate
2476-74-6

6α-fluoro-1,4,9,16-tetraenepregna-3,20-dione-21-acetate

Conditions
ConditionsYield
With Selectfluor In acetonitrile at -10 - 25℃; for 5h;
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

methylmagnesium chloride
676-58-4

methylmagnesium chloride

methyl iodide
74-88-4

methyl iodide

2-oxo-2-((8S,10S,13S,14S,16R,17S)-10,13,16,17-tetramethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate
1201591-22-1

2-oxo-2-((8S,10S,13S,14S,16R,17S)-10,13,16,17-tetramethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate

Conditions
ConditionsYield
Stage #1: 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate; methylmagnesium chloride; copper(II) propionate In tetrahydrofuran Cooling with acetone-dry ice;
Stage #2: methyl iodide In tetrahydrofuran
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

methylmagnesium chloride
676-58-4

methylmagnesium chloride

1-(Trimethylsilyl)imidazole
18156-74-6

1-(Trimethylsilyl)imidazole

(Z)-2-((8S,10S,13S,14S,16R)-10,13,16-trimethyl-3-oxo-7,8,12,13,15,16-hexahydro-3H-cyclopenta[a]phenanthren-17(6H,10H,14H)-ylidene)-2-(trimethylsilyloxy)ethyl acetate
1201591-18-5

(Z)-2-((8S,10S,13S,14S,16R)-10,13,16-trimethyl-3-oxo-7,8,12,13,15,16-hexahydro-3H-cyclopenta[a]phenanthren-17(6H,10H,14H)-ylidene)-2-(trimethylsilyloxy)ethyl acetate

Conditions
ConditionsYield
1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; copper(II) propionate In tetrahydrofuran; dichloromethane at -50 - -30℃; Inert atmosphere;
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

17α,21-dihydroxy-16α-methyl-1,4,9(11)-pregnatriene-3,20-dione 21-acetate
10106-41-9

17α,21-dihydroxy-16α-methyl-1,4,9(11)-pregnatriene-3,20-dione 21-acetate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; copper(II) propionate / dichloromethane; tetrahydrofuran / -50 - -30 °C / Inert atmosphere
2: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 °C
View Scheme
Multi-step reaction with 2 steps
1.1: dichloromethane; tetrahydrofuran / 3 h / 20 °C / Inert atmosphere
1.2: 3 h / 20 °C / Inert atmosphere
1.3: -50 °C / Inert atmosphere
2.1: acetic acid; peracetic acid / toluene / 0.5 h / -10 °C / Inert atmosphere
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

(8S,10S,13S,14S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
111669-38-6

(8S,10S,13S,14S,16R,17S)-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; copper(II) propionate / dichloromethane; tetrahydrofuran / -50 - -30 °C / Inert atmosphere
2: hydrogenchloride; water / ethyl acetate
3: triethylsilane / Wilkinson's catalyst / dichloromethane / 40 °C
4: potassium carbonate; water / dichloromethane; methanol / 2 h / 5 °C / Inert atmosphere; Cooling with ice
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

16α-methyl-21-hydroxypregna-1,4,9(11)-triene-3,20-dione
56016-90-1

16α-methyl-21-hydroxypregna-1,4,9(11)-triene-3,20-dione

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; copper(II) propionate / dichloromethane; tetrahydrofuran / -50 - -30 °C / Inert atmosphere
2: hydrogenchloride; water / ethyl acetate
3: potassium carbonate; water / dichloromethane; methanol / 2 h / 5 °C / Inert atmosphere; Cooling with ice
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

2-oxo-2-((8S,10S,13S,14S,16R,17S)-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate
4258-83-7

2-oxo-2-((8S,10S,13S,14S,16R,17S)-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)ethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; copper(II) propionate / dichloromethane; tetrahydrofuran / -50 - -30 °C / Inert atmosphere
2: hydrogenchloride; water / ethyl acetate
View Scheme
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

2-oxo-2-((8S,10S,13S,14S,16R,17S)-10,13,16-trimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate
177180-83-5

2-oxo-2-((8S,10S,13S,14S,16R,17S)-10,13,16-trimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethyl acetate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; copper(II) propionate / dichloromethane; tetrahydrofuran / -50 - -30 °C / Inert atmosphere
2: hydrogenchloride; water / ethyl acetate
3: triethylsilane / Wilkinson's catalyst / dichloromethane / 40 °C
View Scheme
chloro-trimethyl-silane
75-77-4

chloro-trimethyl-silane

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

methylmagnesium chloride
676-58-4

methylmagnesium chloride

C27H38O4Si

C27H38O4Si

Conditions
ConditionsYield
Stage #1: methylmagnesium chloride With copper dichloride In tetrahydrofuran at 3℃; for 0.0166667h; Inert atmosphere;
Stage #2: 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate In tetrahydrofuran at 3℃; for 0.0333333h; Grignard Reaction; Inert atmosphere;
Stage #3: chloro-trimethyl-silane; methylmagnesium chloride In tetrahydrofuran at 2℃; for 0.2h; Inert atmosphere;
2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
37413-91-5

2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate

17α,21-dihydroxy-9β,11β-epoxy-16α-methylpregna-1,4-diene-3,20-dione 21-acetate
2884-51-7

17α,21-dihydroxy-9β,11β-epoxy-16α-methylpregna-1,4-diene-3,20-dione 21-acetate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: perchloric acid / water / 20 - 27 °C / Inert atmosphere
1.2: 20 - 35 °C / Inert atmosphere
2.1: potassium carbonate / water; acetone / 40 - 46 °C / Inert atmosphere
3.1: copper dichloride / tetrahydrofuran / 0.02 h / 3 °C / Inert atmosphere
3.2: 0.03 h / 3 °C / Inert atmosphere
3.3: 1.75 h / 2.5 °C / Inert atmosphere
4.1: peracetic acid; acetic acid / dichloromethane / 18 h / 4 - 20 °C / Inert atmosphere
View Scheme

37413-91-5Relevant articles and documents

Optimization of the synthesis of a key intermediate for the preparation of glucocorticoids

Jouve, Romain,Thery, Vincent,Ducki, Sylvie,Helfenbein, Julie,Thiery, Jean-Christophe,Job, Aurélie,Picard, Elodie,Mallet, Christophe,Ripoche, Isabelle,Bennis, Khalil

, p. 14 - 21 (2018)

A short and efficient synthesis, based on a one-step double elimination, of a key intermediate in the synthesis of various glucocorticosteroids has been developed. This method can be carried out on large scale for further industrial applications. The synthesis allowed us to identify a novel prednisolone derivative 10 and its anti-inflammatory activity was determined in an in vivo model of inflammation. In order to understand the regioselectivity of the double elimination under various conditions, mechanistic studies were undertaken and confirmed the experimental results. We also propose a mechanism for the formation of the new steroid 10 studied by molecular modeling.

An efficient procedure for the synthesis of 21-acetoxypregna-1,4,9(11),16-tetraene-3,20-dione

Huy, Luu D.,Diep, Nguyen T.,Vu, Tran K.,Savinova, Tatiana S.,Donova, Marina V.

, p. 225 - 231 (2020/04/27)

Background: Halogenated corticosteroids are widely used in medicine, and the global need of these steroidal APIs is estimated to be 40 - 70 tons, annually. Vietnam currently imports the pharmaceutical compounds up to 90%, in particular 100% of steroidal drugs. Currently, industrial production is based on the chemical syntheses of corticosteroids from either 16-dehydropregnenolone acetate (obtained from diosgenin) or androstenedione (obtained from phytosterol). The development of shorter synthetic schemes and more economically feasible technologies is of great significance. Introduction of 1(2)-double bond at the final stages of the corticosteroids synthesis results inpoor yield. 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione (tetraene acetate) is a key intermediate in the synthesis of highly active halogenated corticosteroids such as dexamethasone and other halogenated corticosteroids. 21-acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is a key intermediate in the synthesis of dexamethasone from the readily available and cheap 9α-hydroxyandrost-4-ene-3,17-dione. Objective: The purpose of this study was the development of an efficient and shorter procedure for the synthesis of 21-acetoxypregna-1,4,9(11),16-tetraene-3,20-dione from 9α-hydroxyan-drostenedione, which is a product of a bio-oxidative degradation of the side chain of phytosterols. Methods: Pregnane side chain was constructed using cyanohydrin method. For 1(2)-dehydrogenation, selene dioxide was applied for the introduction of Δ1(2)-double bond. Other stages of the synthesis were epimerization, Stork’s iodination procedure and dehydration. Result: 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione was prepared from 9α-hydroxyandrostenedione in yield more than 46%. Conclusion: An efficient and practically feasible procedure for the synthesis of 21-acetoxypregna-1,4,9(11),16-tetraene-3,20-dione from 9α-hydroxyandrostenedione, a key intermediate for the synthesis of 9-haloidated corticoids, has been developed. The procedure can be applied for the production of value-added 9-haloidated corticoids.

Preparation method of tetraene acetate

-

Paragraph 0066-0086, (2019/12/25)

The invention discloses a preparation method of tetraene acetate. The preparation method of tetraene acetate comprises a step of subjecting a compound 2 as described in the specification, a free radical type halogenating reagent, sulfur dioxide and an acid-binding agent to a reaction in an organic solvent so as to obtain a compound 1 as described in the specification, i.e., tetraene acetate. According to the preparation method, easily and commercially available prednisolone low in price is used as a starting raw material, hydroxyl groups of two different configurations are simultaneously eliminated in the one-step reaction, and intracyclic alkene is formed; and the method is reduced in reaction steps, mild in reaction conditions, simple in aftertreatment, high in yield, high in the chemical purity of a crude product and suitable for industrial production.

Method for preparing tetraene acetate

-

Paragraph 0021-0023; 0026; 0029; 0032; 0035; 0038, (2019/01/07)

The invention provides a method for preparing tetraene acetate. The method comprises the steps of subjecting a raw material, i.e., 17-ynepregna-1,4,9(11)-trien-3-one-17-hydroxyl acetate to a reactionin an organic solvent in the presence of a catalyst, i.e., palladium acetate and an oxidant, i.e., p-benzoquinone under the protection of inert gas so as to produce an intermediate, i.e., 18-hydroxylpregna-1,4,9(11),17-tetraen-3,19-dion-18-acetate, and carrying out treatment by using 1,8-diazabicycloundec-7-ene, thereby obtaining the tetraene acetate (21-hydroxylpregna-1,4,9(11),16-tetraen-3,20-dion-21-acetate)According to the method provided by the invention, the use of palladium chloride, copper chloride and oxygen is avoided, the corrosion to equipment is low, and meanwhile, the purity of the product is improved. The method has the advantages of being safe and efficient, being simple and convenient in operation, being satisfactory for industrial production, and the like and has a relatively high application value.

Preparation method of tetraene acetate

-

, (2018/05/16)

The invention belongs to the technical field of preparation of a steroid hormone drug intermediate, and in particular relates to a preparation method of tetraene acetate. The tetraene acetate is prepared from 1,4,9(11)-triene-androstane-3,17-dione as a raw material sequentially by reaction steps of ethynylation, esterification, bromination and debromination reaction and displacement and elimination reaction, no precious metal catalyst is used in the method, the raw material is easily available, the cost is low, and the reaction is easy to operate. The method is suitable for industrial production. After refining the mass yield by the whole route is more than 88%, and the purity is more than 99%.

Preparation method of delta 16 steroid

-

Paragraph 0077; 0078; 0079; 0080; 0081, (2016/10/07)

The invention relates to a preparation method of a delta 16 steroid. At the atmosphere of protective gas, a compound of a formula II, an oxidizing agent and sulfur dioxide are subjected to a reaction in an organic solvent, the reaction temperature ranges from minus 50 DEG C to 0 DEG C, and the reaction time is 1.5-2.5 h to obtain a delta 16 steroid I, wherein R1 is selected from H, halogen and acyloxy or hydroxide of C1-5; R2 is selected from alkyl of alpha C1-3 and alkyl or H of beta C1-2; R3 is selected from H, alkyl of alpha C1-3, alkyl of beta C1-2, alpha halogen or beta halogen; R4 and R5 are equal to H or double bonds; R7 is selected from H, and R6 is selected from H, alkyl of C1-3 or acyloxy of C1-5; or R6 and R7 are equal to double bonds. According to the preparation method of the delta 16 steroid, the 17-bit hydroxide compound of the formula II is used as raw materials, and the compound of the formula II is industrially produced and is easy to obtain; the preparation method is mild in reaction condition, no high-temperature strong base or strong acid is needed, fewer by-products are produced, the product yield and purity are high, the yield reaches more than 90%, and the purity reaches more than 93%.

Method for preparing tetraene acetate and derivatives thereof

-

Paragraph 0109, (2016/12/01)

The invention relates to a method for preparing tetraene acetate and derivatives thereof. The method comprises the steps of obtaining a compound II through etherification reaction of a compound I and an etherification agent in the atmosphere of protective gases, obtaining a compound III through addition reaction of the compound II and a reagent A under the action of strong base and hydrolysis and elimination reaction of the compound II and the reagent A in the presence of an acid solution, obtaining a compound IV through substitution reaction and rearrangement reaction of the compound III and acetate, and conducting 1 position dehydrogenation and 2 position dehydrogenation on the compound IV to obtain the tetraene acetate and derivatives thereof. According to the method, the compound I is taken as the raw material and subjected to carbonyl etherification, addition, hydrolysis, elimination, rearrangement and dehydrogenation reaction to obtain the product, the raw material compound I is easy to obtain, cost is low, no precious metal is needed during preparation, reaction conditions are easy to control, operation is convenient, the method is suitable for large-scale industrial production, and the obtained tetraene acetate is an important intermediate for synthesis of dexamethasone, budesonide, betamethasone and other steroidal drugs.

Expedient synthesis of 17α,21-dihydroxy-9β,11β-epoxy- 16αmethylpregna- 1,4-diene-3,20-dione 21-acetate from prednisolone utilising a novel Mattox rearrangement

Hulcoop, David G.,Shapland, Peter D.P.

, p. 1281 - 1287 (2013/11/06)

A six step transformation of prednisolone to 17a,21-dihydroxy-9b,11b-epoxy- 16a-amethylpregna-1,4- diene-3,20-dione 21-acetate has been achieved in 13% unoptimised yield. Novel conditions for effecting a Mattox rearrangement and double dehydration of prednisolone were identified. Enhanced knowledge on the oxidation of silyl D19,20-enol ethers and structural factors that impact the success of the oxidation are also presented.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 37413-91-5